Blog - TriNetX

Breaking Down SCOPE 2025: What’s Next for Clinical Trials?

Breaking Down SCOPE 2025: What’s Next for Clinical Trials?

SCOPE 2025, held from February 3-6 in Orlando, Florida, brought together over 4,500 leaders in clinical operations and research to discuss the latest advancements in clinical trial innovation, planning, management, and operations. The TriNetX team was in full force,...
SCOPE 2025: Putting Patients at the Heart of Research

SCOPE 2025: Putting Patients at the Heart of Research

Clinical trials are the bedrock of medical advancement, but they often grapple with a persistent challenge: ensuring diverse and representative participation. This issue isn’t just a matter of ethics—it’s crucial for delivering effective, equitable healthcare...
TriNetX’s Founding CEO Announces Plans to Step Down

TriNetX’s Founding CEO Announces Plans to Step Down

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board   CAMBRIDGE, MA – January 9, 2025 – TriNetX, the largest global source of real-world data, today announced that Gadi Lachman, the Company’s Founder, President and CEO, will step...
With new diversity guidance, EHR data plus AI will be critical

With new diversity guidance, EHR data plus AI will be critical

In June 2024, the U.S. Food and Drug Administration (FDA) issued draft guidance outlining the need for “Diversity Action Plans” as a way for clinical trial sponsors to demonstrate their consideration toward trial representation. Affecting phase 3 studies, and others...